NCT02879097 is a Phase 3 clinical trial of CBT124 in Non-Small Cell Lung Carcinoma, sponsored by Cipla BioTec Pvt. Ltd..

Who is sponsoring NCT02879097?

NCT02879097 is sponsored by Cipla BioTec Pvt. Ltd..

What drugs are being tested in NCT02879097?

Interventions in NCT02879097: CBT124, EU-sourced Avastin®, Carboplatin, Paclitaxel.

What condition does NCT02879097 study?

NCT02879097 studies Non-Small Cell Lung Carcinoma.

Is NCT02879097 still recruiting?

NCT02879097 is currently status unknown. Last updated 22 August 2016.

Last reviewed 2016-08-22 · How we verify

NCT02879097

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC)

Status unknown Phase 3 Last updated 22 August 2016

What this trial tests

Phase 3 trial testing CBT124 in Non-Small Cell Lung Carcinoma in 200 participants. Status unknown.

Timeline

1 December 2016

Primary endpoint
1 December 2017

1 May 2018

Quick facts

Lead sponsor	Cipla BioTec Pvt. Ltd.
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	200
Start date	1 December 2016
Primary completion	1 December 2017
Estimated completion	1 May 2018

Drugs / interventions tested

CBT124 — full drug profile →
EU-sourced Avastin® — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Non-Small Cell Lung Carcinoma — all drugs for Non-Small Cell Lung Carcinoma →

Sponsor

Cipla BioTec Pvt. Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Non-Small Cell Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Objective Response Rate (ORR)
Time frame: 19 weeks
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) criteria (version 1.1). Defined as the proportion of subjects whose best confirmed overall response over Week 1 to Week 19 is either Complete Response (CR) or Partial Response (PR). Confirmed best overall response (complete or partial response) may be claimed only if the criteria for each are met after a repea

Sponsor's own description

The purpose of this study is to determine whether CBT124 and Avastin® are comparable in terms of efficacy, safety, immunogenicity; and whether the pharmacokinetics of CBT124 matches that of Avastin® (pharmacokinetics is nested in this study for Indian patients).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.
Rosen LS, Jacobs IA, Burkes RL. · · 2017 · cited 114× · PMID 28801849 · DOI 10.1007/s11523-017-0518-1
Monoclonal antibody biosimilars for cancer treatment.
Broer LN, Knapen DG, de Groot DA, Mol PGM, et al · · 2024 · cited 4× · PMID 38974466 · DOI 10.1016/j.isci.2024.110115
Biosimilar monoclonal antibodies for cancer treatment in adults.
Galvao TF, Livinalli A, Lopes LC, Zimmermann IR, et al · · 2024 · cited 2× · PMID 39607013 · DOI 10.1002/14651858.cd013539.pub2

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Carcinoma

Currently open trials in the same condition.

NCT07144280 — A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ · Phase 3 · recruiting
NCT06222489 — Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT · Phase 2 · recruiting
NCT05358249 — Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · Phase 1, PHASE2 · active not recruiting
NCT04585750 — The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · Phase 1, PHASE2 · recruiting
NCT03731585 — Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02879097 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cipla BioTec Pvt. Ltd.
Last refreshed: 22 August 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02879097.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing